Fundació URV posted this:Environmentally friendly processing of thermosets by two-stage sequential aza-Michael addition and free-radical polymerization of amine-acrylate mixturesEnvironmentally friendly preparation of thermosets for applications on thermosensitive substrates. A two-step curing process, which consists in an Aza-Michael addition at room temperature, followed by UV radical polymerization of acrylates or methacrylates amine formulations without the need of adding solvents. The presence of amines in the structure suppress the radical inhibition by oxygen, which is a typical drawback in radical polymerizations. The invention allows leading the curing in two separate stages with a stable intermediate material, being the process controlled by the amount of amine in the formulation.
Universidad de Alicante posted this:Novel self-expanding polyurethane foams intended for inert filling of pleural and other human cavities.The Adhesion and Adhesives Laboratory of the University of Alicante has developed a new polymeric foaming material for in-situ filling and sealing of internal irregular different shaped human cavities, intended for patients suffering chronic pleural cavities and in-field injuries caused by bullets or accidental event leaving open blood vessels. The new foam is composed of two separate liquid components that can be mixed in a two-body syringe in such a way that the foaming time can be modulated for allowing the foam formation at the end of the syringe needle. The new polymeric foam can self-expanded and self-modelated for avoiding complications in open internal cavities caused by infections, blooding, fistulae, dyspnea or sepsis. The new foam is easily applicable, safe for biological tissues, and its use avoid the use of the current aggressive treatments in pleural cavities. It is looking for companies interested in acquiring this technology for its commercial exploitation.
Institute of Chemical Research of Catalonia posted this:ERTFlow: flow reaction technologies and process intensificationERTFLOW is a technology development unit from the Institute of Chemical Research of Catalonia (ICIQ), generated by the know-how produced by the research group of Prof. Miquel Pericàs, to develop and implement technical solutions in process intensification. Our goal is to develop propietary technologies related to catalysis and flow chemistry and offering products and services to the fine chemical, pharmaceutical and biotechnological industries for the production of new products with high added value and guide them in the paradigm change from batch to flow.
Universidad de Alcalá-OTRI posted this:New organo-metallic catalysts for the manufacture of polymersA research group from the Inorganic Chemistry Department of Alcalá University has developed a technology that presents a range of catalysts based on coordination complexes and organometallic, active in functionalization processes (expoditation, hydrosilylation) and polymerization of different organic substrates (olefins and cyclic esters). They are metal complexes belonging to the first transition groups (groups 4-6) and elements from the main groups (groups 1,2 and 13). Its application is aimed at the synthesis of materials with new properties (silicon polymers, biodegradable plastics, polyesters) and the production of small molecules with high added value, used as starting products in many industrial processes (epoxides, silanes). The group is looking for manufacturing agreements and joint venture agreements with companies from the agrofood industry, construction and petrochemicals.
Fundació URV posted this:Acrylic thermosets prepared by dual curing at room temperature fit for coatings and adhesivesFormulations for the preparation of thermosets by dual curing, at room temperature in two stages, stable over time, from the reaction of amine compounds with 2 or more N-H bonds with a vinyl compounds with a minimum of 2 double α, β- conjugated bonds to carbonyl ester groups and further polymerization of vinyl groups in excess, with completely controlled characteristics of the material at the intermediate stage.
Universidad de Alicante posted this:New family of dyesThe main innovative aspects of this technology regarding current methods of synthesis are: • The indolizine dyes are obtained in one step from commercially available materials, unlike current procedures, which involve multiple steps. This is an advantage in the production process, as it reduces costs, increases the final yield and less waste is generated. • The procedure is based on a very simple treatment which produces indolizine dyes in yields higher than 70%. • The present invention does not require the use of inert atmosphere, dry solvents or physical activation (heat or radiation) to obtain the final product. • Unlike other methodologies for preparing indolizine dyes (requiring temperatures around 100°C), this process is carried out at room temperature and atmospheric pressure, which simplifies the method and decreases production costs. • This is an environmentally friendly technology because it does not use solvents such as dioxane, pyridine, chloroform or benzene, which are used in other methods and are characterized by their high toxicity and demonstrated carcinogenicity. • The selectivity of the reaction is very high. The indolizine dye is obtained with absolute control, obtaining a single isomer of the ten possible.
Technology Transfer Office
RAMOT at Tel Aviv University Ltd. posted this:Iron oxide nanoparticles (IOP) for the treatment of acute myocardial infarction (AMI) and other inflammatory conditionsA novel approach for the treatment of AMI has been developed using IOPs. IOPs, when injected into the infarcted myocardium, lead to improved heart function after MI. IOPs activate anti-inflammatory macrophages and thus promote tissue healing and repair and prevent myocardial remodeling and dysfunction. Potential Applications IOPs can be used to treat AMI and other inflammatory conditions associated with pro-inflammatory activated macrophages and to promote tissue healing and repair. Advantages ? IOPs are nontoxic ? IOPs are FDA approved for use in humans for MRI imaging Stage In vivo studies in mouse and rat models of MI and heart failure Project ID : 10-2011-247
Ivan Rodriguez Rosello posted this:
Licensing Manager at Universidad de Alicante